SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose 9.5% Stake in Plus Therapeutics

AIGH Capital Management LLC and Orin Hirschman have jointly disclosed a 9.5% beneficial ownership stake in Plus Therapeutics, Inc., totaling 560,905 common shares.

Summary

• Orin Hirschman and AIGH Capital Management LLC, along with AIGH Investment Partners, L.L.C., have jointly filed a Schedule 13G, reporting beneficial ownership in Plus Therapeutics, Inc.
• The reporting persons collectively beneficially own 560,905 shares of Plus Therapeutics, Inc. Common Stock.
• This aggregate amount represents 9.5% of the issuer's class of securities.
• The reported ownership includes sole voting power and sole dispositive power over all 560,905 shares.
• The filing explicitly states that 4,253,282 common shares issuable upon the exercise of warrants are excluded from the reported beneficial ownership, as they are not currently exercisable due to beneficial ownership limitations on exercise.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Plus Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an investment entity and its principal, indicating a substantial stake in Plus Therapeutics, Inc. Such disclosures are common in the financial industry and provide transparency regarding major shareholders.

Related Party Transactions

• The filing details the joint ownership by AIGH Capital Management, LLC, AIGH Investment Partners, L.L.C., and Mr. Orin Hirschman, who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, indicating a related group of reporting persons.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.5% stake by a specific investment group provides transparency regarding the company's ownership structure. The existence of 4,253,282 unexercised warrants, if eventually exercised, could lead to dilution for existing shareholders, although they are currently limited by beneficial ownership restrictions.

Key Dates

Keywords

Plus Therapeutics, AIGH Capital Management, Orin Hirschman, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Partners